All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

arformoterol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
bronchodilators, phenethylamine derivatives	4943	67346-49-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: arformoterol arformoterol tartrate brovana CGP-25827A	the (R,R)-enantiomer of formoterol, is a selective long-acting beta2-adrenergic receptor agonist (beta2-agonist) that has two-fold greater potency than racemic formoterol Molecular weight: 344.41 Formula: C19H24N2O4 CLOGP: 1.26 LIPINSKI: 0 HAC: 6 HDO: 4 TPSA: 90.82 ALOGS: -3.92 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Oct. 6, 2006	FDA	SUNOVION

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic obstructive pulmonary disease	79.74	29.15	36	1409	53399	50550280
Dyspnoea	54.71	29.15	72	1373	547536	50056143
Pneumonia	33.36	29.15	47	1398	378354	50225325

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dyspnoea	61.94	36.88	53	595	326679	29247200
Chronic obstructive pulmonary disease	56.19	36.88	24	624	40931	29532948

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic obstructive pulmonary disease	112.10	24.81	50	1822	70998	64425862
Dyspnoea	79.32	24.81	100	1772	718574	63778286
Pneumonia	35.17	24.81	60	1812	559516	63937344

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000009922	Adrenergic beta2-Agonists
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D000322	Adrenergic Agonists
MeSH PA	D058666	Adrenergic beta-2 Receptor Agonists
MeSH PA	D000318	Adrenergic beta-Agonists
MeSH PA	D018927	Anti-Asthmatic Agents
MeSH PA	D001993	Bronchodilator Agents
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D019141	Respiratory System Agents
FDA EPC	N0000175779	beta2-Adrenergic Agonist
CHEBI has role	CHEBI:35522	beta-adrenergic agonists
CHEBI has role	CHEBI:35523	bronchodilator
CHEBI has role	CHEBI:49167	anti-asthmatic drugs

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chronic obstructive lung disease	indication	13645005	DOID:3083
Chronic bronchitis	indication	63480004	DOID:6132
Pulmonary emphysema	indication	87433001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.23	acidic
pKa2	12.47	acidic
pKa3	8.49	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN	AGONIST	Kd	8.54		SCIENTIFIC LITERATURE	DRUG LABEL
Beta-3 adrenergic receptor	GPCR	P13945	ADRB3_HUMAN		EC50	7.60		CHEMBL
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN	AGONIST	Kd	6.95		SCIENTIFIC LITERATURE
Beta-2 adrenergic receptor	GPCR		ADRB2_CAVPO		EC50	9.90		CHEMBL

External reference:

ID	Source
F91H02EBWT	UNII
D02981	KEGG_DRUG
4026108	VUID
N0000176102	NUI
200815-49-2	SECONDARY_CAS_RN
4026108	VANDF
4026109	VANDF
C0969589	UMLSCUI
CHEBI:408174	CHEBI
H98	PDB_CHEM_ID
CHEMBL1363	ChEMBL_ID
3083544	PUBCHEM_CID
DB01274	DRUGBANK_ID
CHEMBL1951071	ChEMBL_ID
CHEMBL1200811	ChEMBL_ID
CHEMBL3989798	ChEMBL_ID
D000068759	MESH_DESCRIPTOR_UI
8398	INN_ID
7479	IUPHAR_LIGAND_ID
304962	RXNORM
347152	MMSL
88699	MMSL
d05893	MMSL
423317005	SNOMEDCT_US
423347007	SNOMEDCT_US
427097003	SNOMEDCT_US
011766	NDDF
011767	NDDF

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Arformoterol tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	0093-5955	SOLUTION	15 ug	RESPIRATORY (INHALATION)	ANDA	32 sections
Arformoterol tartrate	Human Prescription Drug Label	1	62332-633	SOLUTION	15 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
Arformoterol Tartrate	Human Prescription Drug Label	1	62756-277	SOLUTION	15 ug	RESPIRATORY (INHALATION)	ANDA	30 sections
Brovana	HUMAN PRESCRIPTION DRUG LABEL	1	63402-911	SOLUTION	15 ug	RESPIRATORY (INHALATION)	NDA	32 sections
Brovana	HUMAN PRESCRIPTION DRUG LABEL	1	63402-911	SOLUTION	15 ug	RESPIRATORY (INHALATION)	NDA	32 sections
ARFORMOTEROL TARTRATE	HUMAN PRESCRIPTION DRUG LABEL	1	68462-833	SOLUTION	15 ug	RESPIRATORY (INHALATION)	ANDA	27 sections
arformoterol tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	69097-168	SOLUTION	15 ug	RESPIRATORY (INHALATION)	ANDA	27 sections
Arformoterol Tartrate Inhalation	HUMAN PRESCRIPTION DRUG LABEL	1	70436-151	SOLUTION	15 ug	RESPIRATORY (INHALATION)	ANDA	23 sections
Arformoterol tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	70748-175	SOLUTION	15 ug	RESPIRATORY (INHALATION)	ANDA	28 sections
Arformoterol Tartrate	HUMAN PRESCRIPTION DRUG LABEL	1	70748-257	SOLUTION	15 ug	RESPIRATORY (INHALATION)	NDA authorized generic	27 sections